8-K: Notable Labs Announces Phase 2 Trial Design for Volasertib in Acute Myeloid Leukemia

Notable Labs has released a white paper detailing the design of its Phase 2 trial for Volasertib in relapsed/refractory Acute Myeloid Leukemia (AML), incorporating enhanced antibiotic prophylaxis, tailored dosing, and its Predictive Medicine Platform.

Summary

• Notable Labs is developing Volasertib, a PLK-1 inhibitor, for the treatment of relapsed/refractory Acute Myeloid Leukemia (AML).
• Previous Phase 2 trials of Volasertib by Boehringer Ingelheim (BI) showed a 30% response rate and a statistically significant overall survival benefit.
• A subsequent Phase 3 trial by BI failed to reproduce the survival benefit, likely due to inconsistent antibiotic prophylaxis and fixed dosing.
• Notable's Phase 2 trial design incorporates Western standard antibiotic prophylaxis and patient-tailored dosing based on body surface area (BSA).
• Notable's trial will also use its Predictive Medicine Platform (PMP) to selectively enroll patients predicted to respond to Volasertib.
• The PMP has demonstrated an average 97% predictive precision for 11 AML treatments in previous clinical trials.
• Notable's PMP identified 19 out of 41 AML patient samples as highly sensitive to Volasertib.
• A 30% response rate in Notable's trial would be a significant improvement over the current standard of care for relapsed/refractory AML, which has a response rate of approximately 15%.

Sentiment

Score: 7

Explanation: The document presents a positive outlook for the Phase 2 trial, highlighting the potential for improved outcomes. However, it also acknowledges the risks and uncertainties associated with drug development, resulting in a moderately positive sentiment.

Positives

• Volasertib has shown promising results in previous Phase 2 trials with a 30% response rate and a statistically significant overall survival benefit.
• Notable's trial design addresses the issues identified in Boehringer Ingelheim's Phase 3 trial by implementing Western standard antibiotic prophylaxis and tailored dosing.
• The use of Notable's Predictive Medicine Platform (PMP) is expected to increase the response rate by selecting patients most likely to benefit from Volasertib.
• The PMP has a high predictive precision of 97% based on previous clinical trials.
• The potential for a 30% response rate would be a significant improvement over the current standard of care for relapsed/refractory AML.

Negatives

• Boehringer Ingelheim's Phase 3 trial failed to reproduce the survival benefit seen in the Phase 2 trial.
• The failure of the Phase 3 trial was attributed to inconsistent antibiotic prophylaxis and fixed dosing, highlighting the importance of these factors.
• The development of Volasertib was discontinued by Boehringer Ingelheim, requiring Notable to take over the program.

Risks

• There are risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment and completion of clinical trials.
• Notable may face challenges in obtaining sufficient additional capital to continue to advance its product candidates.
• There is a risk of not obtaining successful clinical results for product candidates and unexpected costs that may result from clinical trials.
• There is a risk related to the failure to realize any value from product candidates and preclinical programs.
• Notable faces risks associated with its future financial and operating results, including its ability to become profitable.
• Notable's ability to retain key personnel is a risk.
• There are risks associated with managing the requirements of being a public company.
• Notable may not be able to obtain orphan drug designation, and the associated benefits, for any of its drug candidates.
• Notable may not be able to obtain regulatory approval for any of its drug candidates.
• Changes in international, federal, state or local legislative requirements could impact Notable.

Future Outlook

The document contains forward-looking statements regarding Notable's future operations, goals, potential benefits of product candidates, timing of clinical milestones, and cash runway. These statements are subject to risks and uncertainties, and actual results may differ materially.

Management Comments

• Notable is leveraging extensive previous development by Boehringer Ingelheim and Notable's Predictive Medicine Platform.
• Notable's Phase 2 trial design is mitigating risk at several levels.

Industry Context

The announcement is relevant to the pharmaceutical industry, specifically in the area of oncology and hematology. It highlights the challenges in developing effective treatments for AML and the potential of personalized medicine approaches. The use of a predictive platform is a growing trend in drug development.

Comparison to Industry Standards

• The 15% response rate for relapsed/refractory AML is a known industry benchmark, highlighting the unmet need in this area.
• Boehringer Ingelheim's previous Volasertib trials serve as a direct comparison, with the Phase 2 results showing a 30% response rate and the Phase 3 results failing to replicate the survival benefit.
• The use of a predictive platform is a growing trend in the industry, with companies like Foundation Medicine and Guardant Health offering similar services.
• The focus on tailored dosing is also in line with industry trends towards personalized medicine, with companies like Novartis and Roche investing heavily in this area.

Stakeholder Impact

• Shareholders may see potential value in the development of Volasertib and the use of the PMP.
• Patients with relapsed/refractory AML may benefit from a more effective treatment option.
• Employees of Notable Labs are involved in the development and execution of the clinical trial.
• The medical community will be interested in the results of the Phase 2 trial.

Next Steps

• Notable will commence its Phase 2 trial for Volasertib in relapsed/refractory AML.
• Notable will selectively enroll patients predicted to respond by the PMP.

Key Dates

Keywords

Volasertib, Acute Myeloid Leukemia, AML, Predictive Medicine Platform, PMP, Clinical Trial, Phase 2, Boehringer Ingelheim, Antibiotic Prophylaxis, Tailored Dosing, PLK-1 Inhibitor, Relapsed/Refractory AML